KRAS Pathway Alterations in Malignant Pleural Mesothelioma: An Underestimated Player.

Autor: Trassl, Lilith^1,2,3 (AUTHOR) lilith.trassl@helmholtz-muenchen.de, Stathopoulos, Georgios T.^1,2,3 (AUTHOR)

Publikováno v: Cancers. Sep2022, Vol. 14 Issue 17, p4303. 14p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

KRAS signaling in malignant pleural mesothelioma

Autor: Antonia Marazioti, Anthi C Krontira, Sabine J Behrend, Georgia A Giotopoulou, Giannoula Ntaliarda, Christophe Blanquart, Hasan Bayram, Marianthi Iliopoulou, Malamati Vreka, Lilith Trassl, Mario A A Pepe, Caroline M Hackl, Laura V Klotz, Stefanie A I Weiss, Ina Koch, Michael Lindner, Rudolph A Hatz, Juergen Behr, Darcy E Wagner, Helen Papadaki, Sophia G Antimisiaris, Didier Jean, Sophie Deshayes, Marc Grégoire, Özgecan Kayalar, Deniz Mortazavi, Şükrü Dilege, Serhan Tanju, Suat Erus, Ömer Yavuz, Pınar Bulutay, Pınar Fırat, Ioannis Psallidas, Magda Spella, Ioanna Giopanou, Ioannis Lilis, Anne‐Sophie Lamort, Georgios T Stathopoulos

Publikováno v: EMBO Mol. Med.:e13631 (2021)
EMBO Molecular Medicine
EMBO Molecular Medicine, Wiley Open Access, 2021, pp.e13631. ⟨10.15252/emmm.202013631⟩
EMBO Molecular Medicine, 2021, pp.e13631. ⟨10.15252/emmm.202013631⟩
EMBO Molecular Medicine, Vol 14, Iss 2, Pp n/a-n/a (2022)

Malignant pleural mesothelioma (MPM) arises from mesothelial cells lining the pleural cavity of asbestos-exposed individuals and rapidly leads to death. MPM harbors loss-of-function mutations in BAP1, NF2, CDKN2A, and TP53, but isolated deletion of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4507fd1ac84685510c7af0e49a39f44
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=63773